TITLE

PAION INITIATES NEW PLASMINOGEN ACTIVATOR PROGRAM

PUB. DATE
May 2006
SOURCE
Worldwide Biotech;May2006, Vol. 18 Issue 5, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the launch of a plasminogen activator program by Paion AG, a company that focuses on the development of treatment opportunities for stroke and other thrombotic diseases. The program is aimed at serving as a long-term life cycle management tool for Desmoteplase and an option for indications not within the current profile and development program of Desmoteplase.
ACCESSION #
20838256

 

Related Articles

  • Stroke: Widening the therapeutic window? Crunkhorn, Sarah // Nature Reviews Drug Discovery;Aug2008, Vol. 7 Issue 8, p643 

    The article presents a study on different treatment approaches for ischaemic stroke. The only drug that is specifically approved for the treatment of ischaemic stroke is the thrombolytic agent tissue plasminogen-activating factor (tPA), however, it can only be administered within 3 hours after...

  • New stroke guidelines stress speedy treatment. Mullarkey, Tamira // Drug Topics;6/18/2007, Vol. 151 Issue 12, p17 

    The article reports on the guidelines developed by the American Heart Association (AHA) Inc. and the American Stroke Association (ASA) concerning the treatment of ischemic stroke in the U.S. The AHA and ASA stress that the focus of the guidelines is on the utilization of intravenous...

  • Reteplase: A Review of its Use in the Management of Thrombotic Occlusive Disorders. Simpson, Dene; Siddiqui, M. Asif A.; Scott, Lesley J.; Hilleman, Daniel E. // American Journal of Cardiovascular Drugs;2006, Vol. 6 Issue 4, p265 

    Reteplase (Retavase) is a plasminogen activator, mimicking endogenous tissue plasminogen activator (t-PA), a serine protease, converting plasminogen to plasmin and thereby precipitating thrombolysis. It is a third-generation recombinant form of t-PA that operates in the presence of fibrin (i.e....

  • Physiological consequences of loss of plasminogen activator gene function in mice. Carmeliet, Peter; Schoonjans, Luc // Nature;3/31/1994, Vol. 368 Issue 6470, p419 

    Investigates the role of tissue-type (t-PA) and urokinase-type plasminogen activator in the development, reproduction, thrombolysis, thrombosis and macrophage function in mice. Results of inactivation of the t-PA gene; Extensive spontaneous fibrin deposition suffered from plasminogen activator...

  • Progress in managing stroke.  // Consumer Reports on Health;Feb2002, Vol. 14 Issue 2, p2 

    Reports the availability of treatment for strokes. Decline of fatalities from ischemic and hemorrhagic stroke; Effect of thrombolytic drugs on survival rate of patients; Management of high blood pressure and atrial fibrillation.

  • Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Roussel, Benoit D.; Macrez, Richard; Jullienne, Amandine; Agin, Véronique; Maubert, Eric; Dauphinot, Luce; Potier, Marie-Claude; Plawinski, Laurent; Castel, Hervé; Hommet, Yannick; Munuera, Josep; Montaner, Joan; Yepes, Manuel; Ali, Carine; Vivien, Denis // Brain: A Journal of Neurology;Aug2009, Vol. 132 Issue 8, p2219 

    Recombinant tissue-type plasminogen activator (tPA) is the fibrinolytic drug of choice to treat stroke patients. However, a growing body of evidence indicates that besides its beneficial thrombolytic role, tPA can also have a deleterious effect on the ischaemic brain. Although ageing influences...

  • Stroke, Antithrombotics.  // Formulary;Feb2001, Vol. 36 Issue 2, p170 

    Updates on the status of stroke, antithrombotics development in the United States. Drugs and indications; Product type; Proposed indication; Food and Drug Administration (FDA) status. INSET: Selected published literature/Internet information to assist....

  • AMA: Educate patients with signs of stroke to seek urgent treatment.  // Geriatrics;Mar97, Vol. 52 Issue 3, p16 

    Reports on the importance of educating older, at-risk patients about the nature of stroke to they can take full advantage of the clot-dissolving benefits of tissue plasminogen activator (t-PA). Other ways primary care physicians can help patients suffering ischemic stroke.

  • Thrombolytics in Acute Ischaemic Stroke: A Guide to Patient Selection and Optimum Use. Adams, H.P. // BioDrugs;2000, Vol. 13 Issue 2, p115 

    Intravenously administered alteplase (recombinant tissue plasminogen activator; rtPA) is the only medical treatment that has been approved for the management of acute ischaemic stroke. Although rtPA has demonstrated efficacy in improving outcomes of patients with a wide range of neurological...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics